Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Palmoplantar Pustulosis
NCT07000630Terminated
- Sponsor
- Peking University First Hospital
- Start
- Jun 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of deucravacitinib in palmoplantar pustulosis (PPP), sponsored by Peking University First Hospital. Primary endpoint: Primary efficacy endpoint at 16 weeks. Started Jun 2025; status: terminated.
02
Drugs
deucravacitinib
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT07000630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000630.